NEW TREATMENTS TO SLOW DOWN THE PROGRESSION OF MEMORY IMPAIRMENT
With dementia statistics rapidly rising, it is fast becoming a global healthcare crisis. It is estimated that by 2030, 82 million people, globally, will have dementia, which will increase to 150 million by 2050. Dementia costs the UK £26 billion per year; this figure is set to double in the next 25 years, in line with the rise in diagnosis. The reality is that this will place an unsustainable strains on healthcare systems in the UK and across the globe.
Alzheimer’s disease, the most common cause of dementia, is currently incurable. There are various medications designed to help treat symptoms of dementia, but there are no treatments available on the market to slow down or halt the progression of the disease. Which is why research into dementia to find new generation medications is vital to be able to find treatments for memory loss and other symptoms – and ultimately cure the disease.
About Re:Cognition Health
Re:Cognition Health is a leading centre for international final phase clinical trials and is dedicated to changing the future for individuals with memory loss and other symptoms of cognitive impairment. Through providing education, clinical excellence and access to the most advanced treatments available worldwide, the industry-leading team are focused on working towards “a world without dementia”.
Re:Cognition Health is spearheading new drugs in the final-phase of clinical trials as part of international studies. Treatment is designed to slow down the progression of memory impairment– existing medications currently available can only mask the symptoms, whilst the condition is still progressing in the brain at an accelerating rate. In other words, existing drugs just help the dying brain cells to work better, but the new medications are designed to keep the brain cells alive and healthy.
Why Clinical Trials?
Clinical trials are essential for advancing our understanding of medicine and improving the healthcare and quality of life for everyone affected by cognitive impairment and dementia. By participating in an international clinical study, individuals can gain the potential personal benefit of early access to a new treatment, free of charge, which would otherwise not be available on the market for at least another 4-5 years.
Individuals participating in clinical studies also receive an accurate diagnosis with the most advanced diagnostic tools. Participants receive outstanding medical care including comprehensive health screens, MRI scans and PET scans and are monitored regularly throughout the study by a team of cognitive experts. Medical costs are covered by the pharmaceutical company, including travel costs to appointments.
Volunteers also have the opportunity to be part of research, having an important global impact on our ability to treat and find a cure for disease; an invaluable contribution for future generations.
Dr Emer MacSweeney, CEO and Medical Director of Re:Cognition Health, comments: “With the introduction of new biomarkers to detect evidence of Alzheimer’s disease at its earliest stage, there is reason for cautious optimism that new generation medications will delay progression of disease and also boost cognition.
Just as research through clinical studies has improved our outlook for numerous diseases including previously fatal infections and certain forms of cancer; the same action is being taken today for Alzheimer’s disease and cognitive impairment. With every study conducted we understand more about the disease and become closer to finding treatments, and ultimately a cure”.
There are many different causes of dementia; Alzheimer’s disease (the most common form, is responsible for 62% of cases in the UK), vascular dementia, Lewy body disease, frontotemporal dementia, mild cognitive impairment(MCI) and Parkinson’s disease are amongst the most common. Damage to different parts of the brain are associated with different types of dementia. Re:Cognition Health is enrolling patients on international clinical trials for new generation medications for:
- Alzheimer’s disease
- Cerebrovascular disease
- Frontotemporal dementia
Lewy Body disease - Mild cognitive impairment
- Parkinson’s disease
For further information on the clinical trials and to register interest, visit https://recognitionhealth.com/our-services/clinical-trials/or call 0808 250 2781 to speak to a friendly member of our team.
Whilst we progress research, the very best treatment is prevention, rather than cure.
Research has indicated the link between a healthy lifestyle and developing dementia. In fact, individuals can reduce their risk by up to 33% by following a healthy diet, exercising regularly, getting enough sleep, socializing, giving up smoking and keeping the brain active. Brain health tips from Dr MacSweeney can be found at:https://recognitionhealth.com/keep-your-brain-healthy/
Re:Cognition Health at the Alzheimer’s Show
You can visit the team on stand D2 to discuss the latest developments in Alzheimer’s treatments research and what’s involved in signing up for a trial. Re:Cognition Health’s CEO and Medical Director, Dr Emer MacSweeney, will be speaking about clinical trials on Saturday 8thJune in the Alzheimer’s Matters Theatre at 14:00 – 14:25.
){kind=logo}
)
)
)
)
){kind=logo}
){kind=logo}
)